Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the post-smtp domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/cwbk.umed.pl/public_html/wp-includes/functions.php on line 6114
Competition ABM/2022/6

Competition ABM/2022/6

The Medical Research Agency has published the Regulations for the Competition dedicated to the entrepreneurs: for the development of targeted or personalised medicine based on nucleic acid and small molecule compounds (ABM/2022/6).

If you collaborate with the private sector entities which conduct activities defined within the Competition frames, you are encouraged to contact the Clinical Trials Support Centre (cwbk@umed.lodz.pl) to discuss the possibility of participating in the Project.

The Competition’s main objective is to strengthen the collaboration between the biopharmaceutical companies and the scientific community and it aims to support the development of innovative medicinal products based on nucleic acids and small-molecule compounds used in targeted or personalised therapies for the treatment or prevention of diseases, including gene therapies, anticancer therapies, RNA construct therapies, vaccines or immunomodulator therapies.

Within the framework of the Competition, it is allowed to submit applications at different phases of development of the Medicinal Product (Phase I, II, III of the Clinical Trial) based on Nucleic Acids or Small Molecule Compounds, with the obligatory objective that at least one full phase of the Clinical Trial will be carried out as a part of the funded Project.

Regardless of the level of advancement of the Project at the time of application submission, it must end with commercialisation.

Funding for the Competition (total): PLN 250 million.

The maximum allowable level of financing for a particular Project will be in accordance to the ABM Public Aid Regulation.

Application Deadline: until 23.02.2023

Maximum duration of the Project: 6 years (72 months)

Required Project start date: no earlier than 28.02.2023 but no later than 30.04.2023.

Extra points at proposal evaluation can be granted if the Project covers the below:

  • The subject of the Project is a minimum phase 2, randomised, double-blinded study: possible 3 extra points.
  • Commercialisation of technologies based on nucleic acid or small molecule compounds therapies will take place within the Applicant’s own business activity in the territory Poland: possible 5 extra points.
  • The project involves conducting a clinical trial based on nucleic acids: possible 5 extra points.
  • The manufacture of a medicinal product based on therapies on nucleic acids or small-molecule compounds for the purposes of a clinical trial in the territory of Poland: possible 5 extra points.

More details available here: LINK

share

Last news